481 related articles for article (PubMed ID: 33140310)
21. RNA binding protein RBM14 promotes radio-resistance in glioblastoma by regulating DNA repair and cell differentiation.
Yuan M; Eberhart CG; Kai M
Oncotarget; 2014 May; 5(9):2820-6. PubMed ID: 24811242
[TBL] [Abstract][Full Text] [Related]
22. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
24. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
Gersey ZC; Rodriguez GA; Barbarite E; Sanchez A; Walters WM; Ohaeto KC; Komotar RJ; Graham RM
BMC Cancer; 2017 Feb; 17(1):99. PubMed ID: 28160777
[TBL] [Abstract][Full Text] [Related]
25. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of malignant glioma.
Alexandru-Abrams D; Jadus MR; Hsu FP; Stathopoulos A; Bota DA
Anticancer Agents Med Chem; 2014; 14(8):1075-84. PubMed ID: 25175690
[TBL] [Abstract][Full Text] [Related]
28. HMGB1-Induced p62 Overexpression Promotes Snail-Mediated Epithelial-Mesenchymal Transition in Glioblastoma Cells via the Degradation of GSK-3β.
Li H; Li J; Zhang G; Da Q; Chen L; Yu S; Zhou Q; Weng Z; Xin Z; Shi L; Ma L; Huang A; Qi S; Lu Y
Theranostics; 2019; 9(7):1909-1922. PubMed ID: 31037147
[No Abstract] [Full Text] [Related]
29. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.
Nakano I; Joshi K; Visnyei K; Hu B; Watanabe M; Lam D; Wexler E; Saigusa K; Nakamura Y; Laks DR; Mischel PS; Viapiano M; Kornblum HI
Neuro Oncol; 2011 Jun; 13(6):622-34. PubMed ID: 21558073
[TBL] [Abstract][Full Text] [Related]
30. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
31. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
32. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
33. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
34. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
35. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
36. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
37. Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure.
Acikgoz E; Güler G; Camlar M; Oktem G; Aktug H
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Feb; 209():150-164. PubMed ID: 30388586
[TBL] [Abstract][Full Text] [Related]
38. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
39. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
40. Glioblastoma cancer stem cell biology: Potential theranostic targets.
Sharifzad F; Ghavami S; Verdi J; Mardpour S; Mollapour Sisakht M; Azizi Z; Taghikhani A; Łos MJ; Fakharian E; Ebrahimi M; Hamidieh AA
Drug Resist Updat; 2019 Jan; 42():35-45. PubMed ID: 30877905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
